MGNX on Nasdaq

MACROGENICS INC

American pharmaceutical preparations company based in Rockville. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with ELITE PHARMACEUTICALS INC /NV/, Clovis Oncology or Karyopharm Therapeutics Inc., or pick any stock.

  • TickerMGNX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersRockville, United States2
  • Incorporated inDE3
  • Business address9704 Medical Center Drive, Rockville, Md 208503
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493001KJQUA83L8MH792
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 32740052

See how the biggest companies compare on our leaderboards

All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-48.7%Operating margin5
-49.9%Net margin5
-0.3%Revenue growth, 20255
-134.2%Return on equity5
-$83.0MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Revenue From Collaborative Agreements brought in 58% of the revenue MACROGENICS INC broke down this way in fiscal 2025.

  1. Revenue From Collaborative Agreements$87.2M558%down 27% from 2024
  2. Contract Manufacturing$52.6M535%up 303% from 2024
  3. Revenue From Royality Agreements$9.7M56%up 1627% from 2024
Products and services by year
Products and services202320242025
Revenue From Collaborative Agreements$30.5M$119.9M$87.2M
Contract Manufacturing$9.8M$13.1M$52.6M
Revenue From Royality Agreements$431.0K$561.0K$9.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development98¢$147.2M
  • Other costs1¢$1.7M
  • Income tax0¢$672.0K

Out of $149.5M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$149.5M in 2025+133% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $64.2M$64.2M20192020: $104.9M$104.9M2020+63%2021: $77.4M$77.4M2021−26%2022: $151.9M$151.9M2022+96%2023: $58.7M$58.7M2023−61%2024: $150.0M$150.0M2024+155%2025: $149.5M$149.5M2025−0%
Operating income67895-$72.8M in 2025−59% since 2019
-$300.0M-$200.0M-$100.0M02019: -$177.2M-$177.2M20192020: -$131.1M-$131.1M2020−26%2021: -$202.8M-$202.8M2021+55%2022: -$121.4M-$121.4M2022−40%2023: -$168.2M-$168.2M2023+39%2024: -$110.6M-$110.6M2024−34%2025: -$72.8M-$72.8M2025−34%
Net income67895-$74.6M in 2025−51% since 2019
-$300.0M-$200.0M-$100.0M02019: -$151.8M-$151.8M20192020: -$129.7M-$129.7M2020−15%2021: -$202.1M-$202.1M2021+56%2022: -$119.8M-$119.8M2022−41%2023: -$9.1M-$9.1M2023−92%2024: -$67.0M-$67.0M2024+639%2025: -$74.6M-$74.6M2025+11%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Total revenues$149.5M$150.0M$58.7M
Cost of product sales$0$847.0K$619.0K
Cost of manufacturing services$36.0M$11.5M$7.6M
Research and development$147.2M$177.2M$166.6M
Selling, general and administrative$39.2M$71.0M$52.2M
Total costs and expenses$222.3M$260.5M$227.0M
Loss from operations-$72.8M-$110.6M-$168.2M
Gain on royalty monetization arrangement$0$0$150.9M
Gain on sale of MARGENZA$0$36.2M$0
Interest and other income$6.1M$9.4M$9.7M
Interest and other expense-$8.5M-$1.1M-$1.4M
Loss before income taxes-$75.3M-$66.0M-$9.1M
Income tax (benefit) expense-$672.0K$944.0K$0
Net loss-$74.6M-$67.0M-$9.1M
Unrealized gain (loss) on investments$28.0K$10.0K-$1.0K
Comprehensive loss-$74.6M-$67.0M-$9.1M
Basic and diluted net loss per common share, basic (in dollars per share)-$1.18-$1.07-$0.15
Basic and diluted net loss per common share, diluted (in dollars per share)-$1.18-$1.07-$0.15
Basic weighted average number of common shares outstanding (in shares)63.2M shares62.6M shares61.9M shares
Diluted weighted average number of common shares outstanding (in shares)63.2M shares62.6M shares61.9M shares

Compare MACROGENICS INC with another company

Leadership

Who has led MACROGENICS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Scott Koenig2013–2025
  2. Eric Blasius Risser2025–now

President

  1. Scott Koenig2013–2025
  2. Eric Blasius Risser2025–now

Chief financial officer

  1. James Karrels2013–now

Chief operating officer

  1. Eric Blasius Risser2022–now
201520202025
Board members and other officers (27)

Timeline

  1. Aug 15, 2025New chief executive Eric Blasius Risser becomes CEO13
  2. Oct 9, 2013New chief executive Scott Koenig becomes CEO14
  3. Aug 14, 2000Founded MACROGENICS INC is founded2

Filings

342 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 58 major events, 166 insider forms, 52 large holders, 46 other. The latest 20:

  1. Oct 7, 20264 EDGAR
  2. Sep 21, 2026144 EDGAR
  3. Sep 3, 2026S-8 EDGAR
  4. Sep 3, 20268-K/A EDGAR
  5. Aug 20, 20264 EDGAR
  6. Aug 19, 2026144 EDGAR
  7. Aug 18, 20264 EDGAR
  8. Aug 17, 2026144 EDGAR
  9. Aug 14, 2026SCHEDULE 13G/A EDGAR
  10. Aug 14, 202610-Q EDGAR
  11. Aug 13, 20268-K EDGAR
  12. Aug 3, 2026144 EDGAR
  13. Aug 3, 2026SCHEDULE 13G/A EDGAR
  14. Jul 29, 2026SCHEDULE 13G EDGAR
  15. Jul 23, 20268-K EDGAR
  16. Jul 20, 2026SCHEDULE 13G/A EDGAR
  17. Jul 13, 2026144 EDGAR
  18. Jul 8, 20268-K EDGAR
  19. Jul 7, 20268-K EDGAR
  20. Jun 5, 2026SCHEDULE 13G EDGAR

The 342 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

30 open-market trades by officers, directors and large owners since October 2021: 16 buys and 14 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 19, 2026Peters Jeffrey StuartSenior VP, GC, and SecretarySale31,105$4.15$129.1KForm 4
Aug 20, 2025HEIDEN WILLIAM KDirectorBuy49,500$1.49$73.8KForm 4
Aug 19, 2025HEIDEN WILLIAM KDirectorBuy50,500$1.52$76.8KForm 4
Feb 15, 2025Smith Beth AnnVP, Controller & TreasurerSale423$2.56$1.1KForm 4
Apr 4, 2024Peters Jeffrey StuartSenior VP, GC, and SecretarySale51,395$15.55$799.1KForm 4
Mar 6, 2024Peters Jeffrey StuartSenior VP, GC, and SecretarySale19,625$21.50$421.9KForm 4
Mar 4, 2024Risser Eric BlasiusPresident and CEOSale41,159$19.76$813.5KForm 4
Mar 4, 2024Spitznagel ThomasSr VP, Technical OpsSale10,000$20.00$200.0KForm 4
Mar 4, 2024Karrels JamesSVP and CFOSale30,000$20.50$615.0KForm 4
Feb 26, 2024Peters Jeffrey StuartSenior VP, GC, and SecretarySale16,124$17.22$277.7KForm 4
Feb 7, 2024Bonvini EzioSr VP, Research & CSOSale3,334$18.00$60.0KForm 4
Feb 5, 2024Peters Jeffrey StuartSenior VP, GC, and SecretarySale76,251$16.50$1.3MForm 4
Feb 1, 2024Bonvini EzioSr VP, Research & CSOSale13,316$15.00$199.7KForm 4
Jan 19, 2024Bonvini EzioSr VP, Research & CSOSale13,316$12.00$159.8KForm 4
Dec 20, 2023Bonvini EzioSr VP, Research & CSOSale18,880$10.08$190.3KForm 4
Oct 2, 2023BB BIOTECH AG10% ownerBuy150,000$4.46$669.0KForm 4
Sep 7, 2023BIOTECH TARGET N V10% ownerBuy200,000$5.26$1.1MForm 4
Aug 30, 2023HURWITZ EDWARDDirectorBuy15,000$4.91$73.7KForm 4
Mar 10, 2023Peters Jeffrey StuartSenior VP, GC, and SecretarySale5,372$6.03$32.4KForm 4
Feb 14, 2023BB BIOTECH AG10% ownerBuy500,000$5.07$2.5MForm 4

All 30 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Armistice Capital, LLC5,006,752$23.1M0.6%−1,005,248
BlackRock, Inc.4,679,229$21.6M0.0%+3,516,083
Vanguard Capital Management LLC2,656,010$12.3M0.0%+2,157
Renaissance Technologies LLC2,632,750$12.2M0.0%−330,809
Bank Of America Corp /de/2,488,252$11.5M0.0%+86,438
Two Sigma Investments, LP2,465,699$11.4M0.0%−62,130
Millennium Management LLC2,374,296$11.0M0.0%−420,061
Wasatch Advisors LP2,018,881$9.3M0.1%+459,180
Ra Capital Management, L.P.1,864,176$8.6M0.1%No change
Vanguard Portfolio Management LLC1,820,231$8.4M0.0%+611,456
Mackenzie Financial Corp1,642,626$7.6M0.0%+1,045,184
Marshall Wace, Llp1,616,220$7.5M0.0%−409,306
Geode Capital Management, LLC1,576,549$7.3M0.0%+879,228
Affinity Asset Advisors, LLC1,216,606$5.6M0.3%+716,606
D. E. Shaw & Co., Inc.1,062,991$4.9M0.0%+4,567
Jacobs Levy Equity Management, Inc1,002,274$4.6M0.0%+561,131
Connor, Clark & Lunn Investment Management Ltd.1,000,412$4.6M0.0%+133,163
State Street Corp863,663$4.0M0.0%+569,976
Goldman Sachs Group Inc558,001$2.6M0.0%+284,523
Northern Trust Corp516,129$2.4M0.0%+363,847
Vanguard Fiduciary Trust Co420,106$1.9M0.0%+80,017
Nomura Asset Management International Inc.420,000$1.9M0.0%No change
Walleye Capital LLC408,150$1.9M0.0%+72,885
Dimensional Fund Advisors LP379,335$1.8M0.0%+127,532
Diadema Partners LP374,403$1.7M0.7%−225,597

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54